
Clotting, Immune System, and Venous Thrombosis in Lung Adenocarcinoma Patients: A Prospective Study
2009; Taylor & Francis; Volume: 27; Issue: 10 Linguagem: Inglês
10.3109/07357900903124464
ISSN1532-4192
AutoresErnesto de Meis, V.R. Pinheiro, Mauro Musa Zamboni, Maria Teresa Santos Guedes, Ilda A.M. Castilho, Maria Mercedes K. Martinez, Marys Stella O. Leda, Neura P. R. Silveira, Vivian M. Rumjanek, Roger A. Levy,
Tópico(s)Inflammatory Biomarkers in Disease Prognosis
ResumoThrombosis is highly prevalent in cancer patients, being accepted as a bad prognosis marker. The importance of various mechanisms involved in the thrombophilic state of lung cancer patients is not well understood. In this prospective study, involving 109 unselected patients with lung adenocarcinoma, thrombosis was present in 24% of patients and affected survival in a bivariable model. However, in a multivariable evaluation, considering all the factors under study, only LAC and IgM anti-β2 GP I modified thrombosis risk, whereas in a Kaplan–Meyer regression model, thrombosis, IL-6, LAC, factor VIII, and IgM anti-β2 GP I interfered with patient's survival.
Referência(s)